<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739466</url>
  </required_header>
  <id_info>
    <org_study_id>LA-II-01</org_study_id>
    <nct_id>NCT00739466</nct_id>
  </id_info>
  <brief_title>Biorest Liposomal Alendronate With Stenting sTudy (BLAST)</brief_title>
  <acronym>BLAST</acronym>
  <official_title>Intravenous Liposomal Alendronate Infusion in Subjects Undergoing Bare Metal Coronary Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BIOrest Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baim Institute for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiovascular Research Foundation, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BIOrest Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and efficacy of Liposomal
      Alendronate in the treatment of de novo stenotic lesions in native coronary arteries in a
      population undergoing PCI with implantation of a bare metal stent.

      Study hypothesis: Liposomal Alendronate will reduce in-stent restenosis as compared to
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II dose-finding, randomized, multi-center, prospective, double blind clinical
      study. Subjects undergoing percutaneous coronary intervention (PCI) with the Presillionâ„¢ CoCr
      bare metal stent will be randomized into three groups and administered (in a single dose
      intravenously (IV) through a peripheral venous catheter) either: low dose Liposomal
      Alendronate of 0.001 mg, high dose Liposomal Alendronate of 0.01 mg, or placebo (IV saline
      infusion) on a 1:1:1 basis.

      All subjects will undergo angiographic follow-up at 6 months and 110 subjects enrolled from
      pre-specified sites will undergo intravascular ultrasound (IVUS) at baseline and follow-up at
      6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late loss: measured at 6 months post-procedure as determined by quantitative coronary angiography (QCA).</measure>
    <time_frame>6 months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>at 30, 180 and 360 days as well as yearly through 5 years post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Alendronate dose of 0.001 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Alendronate dose of 0.01 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Alendronate</intervention_name>
    <description>IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours</description>
    <arm_group_label>low dose</arm_group_label>
    <other_name>LA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Alendronate</intervention_name>
    <description>IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours</description>
    <arm_group_label>high dose</arm_group_label>
    <other_name>LA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline infusion (placebo)</intervention_name>
    <description>IV saline infusion during the index procedure (coronary stent implantation) over 2 hours</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is eligible for percutaneous coronary intervention .

          2. Subject is an acceptable candidate for coronary artery bypass graft surgery.

          3. Subject has stable angina pectoris

          4. Subject is a candidate for elective stenting of up to 2 lesions.

        Exclusion Criteria:

        General

          1. Any planned elective surgery or percutaneous intervention within 6 months
             post-procedure.

          2. A previous coronary interventional procedure of any kind within 30 days prior to the
             procedure.

          3. Subject requires a staged procedure of either the target or any non-target vessel
             within 9 months post-procedure.

          4. Any drug eluting stent (DES) deployment within the past 12 months.

          5. Any planned drug eluting stent (DES) deployment during the procedure associated with
             this study or within 3 months following the index procedure.

          6. Known hypersensitivity or contraindication to aspirin or clopidogrel or a sensitivity
             to contrast media, which cannot be adequately pre-medicated

          7. Concurrent medical condition with a life expectancy of less than 12 months.

          8. Documented left ventricular ejection fraction (LVEF) &lt; 25% at the most recent
             evaluation.

          9. Evidence of ST elevated myocardial infarction (STEMI) or non-STEMI with troponin (cTn)
             levels greater than or equal to 3 times the normal limit at any time within 72 hours
             of the intended trial procedure.

         10. History of cerebrovascular accident or transient ischemic attack in the last 6 months.

         11. Leukopenia .

         12. Neutropenia

         13. Thrombocytopenia

         14. Serum creatinine level &gt;2.5 mg/dl within 7 days prior to index procedure.

         15. History of bleeding diathesis or coagulopathy or inability to accept blood
             transfusions.

         16. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin,
             clopidogrel and ticlopidine, cobalt, nickel, L-605 Cobalt chromium alloy, Alendronate
             or sensitivity to contrast media, which cannot be adequately pre-medicated.

         17. History of severe:Gastrointestinal disease,Immunodeficiency,Bone diseases

        Angiographic Exclusion Criteria

          1. Unprotected left main coronary artery disease (obstruction greater than 50% in the
             left main coronary artery that is not protected by at least one non-obstructed bypass
             graft to the LAD or Circumflex artery or a branch thereof).

          2. Any previous stent placement within 15 mm (proximal or distal) of the target
             lesion(s).

          3. Target vessel exhibiting lesions with greater than 60% diameter stenosis outside of a
             range of 5 mm proximal and distal to the target lesion(s) based on visual estimate or
             on-line QCA.

          4. Target lesion(s) exhibiting an intraluminal thrombus (occupying &gt;50% of the true lumen
             diameter) at any time.

          5. Lesion location that is aorto-ostial or within 5 mm of the origin of the left anterior
             descending (LAD) or left circumflex (LCX).

          6. The target lesion(s) requires treatment with a device other than PTCA prior to stent
             placement (such as, but not limited to, directional coronary atherectomy, excimer
             laser, rotational atherectomy, etc.).

          7. Target lesion(s) with side branches &gt; 2.0mm in diameter.

          8. Target lesion(s) involving a bifurcation (either stenosis of both main vessel and
             major branch or stenosis of just major branch).

          9. Target lesion(s) with severe calcification.

         10. Target vessel exhibiting excessive tortuosity that may impede stent delivery and
             deployment at target lesion(s).

         11. Target lesion(s) located in a native vessel distal to an anastomosis with a saphenous
             vein graft or a left/right internal mammary artery (LIMA/RIMA) bypass.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Shmuel Banai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Tel Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnei Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Davis Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Galilee Hospital, Nahariya</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Baruch Padeh Medical Center, Poriya</name>
      <address>
        <city>Poriya</city>
        <zip>15218</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center, Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52521</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <last_update_submitted>January 17, 2016</last_update_submitted>
  <last_update_submitted_qc>January 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liposomal Alendronate</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Coronary stenting</keyword>
  <keyword>de novo stenotic lesions</keyword>
  <keyword>Native coronary arteries</keyword>
  <keyword>Restenosis</keyword>
  <keyword>Bare metal stent</keyword>
  <keyword>Presillion CoCr coronary stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

